Peringatan Keamanan

Patients with renal impairment or those taking ototoxic and nephrotoxic drugs are at the highest risk for ototoxicity and nephrotoxicity associated with aminoglycoside use.
Normal duration of IM or IV aminoglycoside therapy is 7-10 days. Although a longer duration may be necessary in some cases, toxicity is more likely to occur when aminoglycoside treatment is continued for longer than 10 days.

Arbekacin

DB06696

small molecule experimental investigational

Deskripsi

An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).

Struktur Molekul 2D

Berat 552.619
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Aminoglycosides are not well absorbed from the gastrointestinal tract. Their absorption is markedly improved by parenteral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

868 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Arbekacin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Arbekacin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Arbekacin.
Cisatracurium Arbekacin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Arbekacin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Arbekacin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Arbekacin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Arbekacin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Arbekacin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Arbekacin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Arbekacin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Arbekacin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Arbekacin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Arbekacin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Arbekacin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Arbekacin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Arbekacin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Arbekacin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Arbekacin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Arbekacin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Arbekacin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Arbekacin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Arbekacin.
Tenofovir disoproxil Arbekacin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Arbekacin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Arbekacin may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Arbekacin.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Incadronic acid.
Taxifolin The risk or severity of nephrotoxicity can be increased when Taxifolin is combined with Arbekacin.
Licofelone The risk or severity of nephrotoxicity can be increased when Licofelone is combined with Arbekacin.
Polmacoxib The risk or severity of nephrotoxicity can be increased when Polmacoxib is combined with Arbekacin.
Ebselen The risk or severity of nephrotoxicity can be increased when Ebselen is combined with Arbekacin.
Flurbiprofen axetil The risk or severity of nephrotoxicity can be increased when Flurbiprofen axetil is combined with Arbekacin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Arbekacin is combined with Acetyldigitoxin.
Deslanoside The risk or severity of adverse effects can be increased when Arbekacin is combined with Deslanoside.
Ouabain The risk or severity of adverse effects can be increased when Arbekacin is combined with Ouabain.
Digitoxin The risk or severity of adverse effects can be increased when Arbekacin is combined with Digitoxin.
Oleandrin The risk or severity of adverse effects can be increased when Arbekacin is combined with Oleandrin.
Cymarin The risk or severity of adverse effects can be increased when Arbekacin is combined with Cymarin.
Proscillaridin The risk or severity of adverse effects can be increased when Arbekacin is combined with Proscillaridin.
Metildigoxin The risk or severity of adverse effects can be increased when Arbekacin is combined with Metildigoxin.
Lanatoside C The risk or severity of adverse effects can be increased when Arbekacin is combined with Lanatoside C.
Gitoformate The risk or severity of adverse effects can be increased when Arbekacin is combined with Gitoformate.
Acetyldigoxin The risk or severity of adverse effects can be increased when Arbekacin is combined with Acetyldigoxin.
Peruvoside The risk or severity of adverse effects can be increased when Arbekacin is combined with Peruvoside.
Torasemide The serum concentration of Arbekacin can be increased when it is combined with Torasemide.
Bumetanide The serum concentration of Arbekacin can be increased when it is combined with Bumetanide.
Etacrynic acid The serum concentration of Arbekacin can be increased when it is combined with Etacrynic acid.
Piretanide The serum concentration of Arbekacin can be increased when it is combined with Piretanide.
Azosemide The serum concentration of Arbekacin can be increased when it is combined with Azosemide.
Tripamide The serum concentration of Arbekacin can be increased when it is combined with Tripamide.
Flucloxacillin The serum concentration of Arbekacin can be decreased when it is combined with Flucloxacillin.
Phenoxymethylpenicillin The serum concentration of Arbekacin can be decreased when it is combined with Phenoxymethylpenicillin.
Dicloxacillin The serum concentration of Arbekacin can be decreased when it is combined with Dicloxacillin.
Carbenicillin The serum concentration of Arbekacin can be decreased when it is combined with Carbenicillin.
Nafcillin The serum concentration of Arbekacin can be decreased when it is combined with Nafcillin.
Hetacillin The serum concentration of Arbekacin can be decreased when it is combined with Hetacillin.
Benzylpenicilloyl polylysine The serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicilloyl polylysine.
Mezlocillin The serum concentration of Arbekacin can be decreased when it is combined with Mezlocillin.
Cyclacillin The serum concentration of Arbekacin can be decreased when it is combined with Cyclacillin.
Benzylpenicillin The serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicillin.
Azlocillin The serum concentration of Arbekacin can be decreased when it is combined with Azlocillin.
Cloxacillin The serum concentration of Arbekacin can be decreased when it is combined with Cloxacillin.
Amdinocillin The serum concentration of Arbekacin can be decreased when it is combined with Amdinocillin.
Bacampicillin The serum concentration of Arbekacin can be decreased when it is combined with Bacampicillin.
Meticillin The serum concentration of Arbekacin can be decreased when it is combined with Meticillin.
Pivampicillin The serum concentration of Arbekacin can be decreased when it is combined with Pivampicillin.
Pivmecillinam The serum concentration of Arbekacin can be decreased when it is combined with Pivmecillinam.
Ticarcillin The serum concentration of Arbekacin can be decreased when it is combined with Ticarcillin.
Azidocillin The serum concentration of Arbekacin can be decreased when it is combined with Azidocillin.
Carindacillin The serum concentration of Arbekacin can be decreased when it is combined with Carindacillin.
Sultamicillin The serum concentration of Arbekacin can be decreased when it is combined with Sultamicillin.
Temocillin The serum concentration of Arbekacin can be decreased when it is combined with Temocillin.
Epicillin The serum concentration of Arbekacin can be decreased when it is combined with Epicillin.
Pheneticillin The serum concentration of Arbekacin can be decreased when it is combined with Pheneticillin.
Carfecillin The serum concentration of Arbekacin can be decreased when it is combined with Carfecillin.
Propicillin The serum concentration of Arbekacin can be decreased when it is combined with Propicillin.
Clometocillin The serum concentration of Arbekacin can be decreased when it is combined with Clometocillin.
Sulbenicillin The serum concentration of Arbekacin can be decreased when it is combined with Sulbenicillin.
Penamecillin The serum concentration of Arbekacin can be decreased when it is combined with Penamecillin.
Talampicillin The serum concentration of Arbekacin can be decreased when it is combined with Talampicillin.
Aspoxicillin The serum concentration of Arbekacin can be decreased when it is combined with Aspoxicillin.
Metampicillin The serum concentration of Arbekacin can be decreased when it is combined with Metampicillin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Arbekacin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Arbekacin.
Lymecycline The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Arbekacin.
Clomocycline The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Arbekacin.
Quinine The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Arbekacin.
Tigecycline The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Arbekacin.
Oxytetracycline The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Arbekacin.
Demeclocycline The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Arbekacin.
Magnesium sulfate The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Arbekacin.
Metacycline The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Arbekacin.
Minocycline The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Arbekacin.

Target Protein

30S ribosomal protein S12 rpsL

Referensi & Sumber

Synthesis reference: Shinichi Kondo, Seiji Shibahara, Takayuki Usui, Toshiaki Kudo, Shuichi Gomi, Atsushi Tamura, Yoko Ikeda, Daishiro Ikeda, Tomio Takeuchi, "Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof." U.S. Patent US5618795, issued October, 1989.
Artikel (PubMed)
  • PMID: 7758395
    Inoue M, Nonoyama M, Okamoto R, Ida T: Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res. 1994;20(6):233-9.
  • PMID: 15620825
    Morikawa K, Nonaka M, Yoshikawa Y, Torii I: Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents. 2005 Jan;25(1):44-50.
  • PMID: 14742200
    Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y: Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother. 2004 Feb;48(2):491-6.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul